TEVA:NYE-Teva Pharmaceutical Industries Limited American Depositary Shares (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 16.12

Change

-0.27 (-1.65)%

Market Cap

USD 38.25B

Volume

0.02B
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Its products include Copaxone, Azilect and Provigil.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+6.12 (+4.08%)

USD 66.32B
HLN Haleon plc

+0.09 (+0.84%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

-0.11 (-0.73%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

+0.01 (+0.07%)

USD 11.39B
ELAN Elanco Animal Health

+2.50 (+26.29%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.04 (+0.56%)

USD 3.25B
BHC Bausch Health Companies Inc

-0.04 (-0.84%)

USD 1.60B
CPHI China Pharma Holdings Inc

+0.02 (+1.08%)

USD 4.61M
YCBD cbdMD Inc

+0.78 (+610.94%)

USD 1.44M
EBS Emergent Biosolutions Inc

-0.05 (-1.04%)

N/A

ETFs Containing TEVA

FLWR:SW 5.80 % 0.00 %

N/A

N/A
ALFI 0.00 % 0.88 %

N/A

N/A
EIS iShares MSCI Israel ETF 0.00 % 0.59 %

+1.53 (+0%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
GWL 0.00 % 0.34 %

N/A

N/A
ISRA VanEck Israel ETF 0.00 % 0.60 %

+0.87 (+0%)

USD 0.09B
ISRPF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

USD 2.22B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

-0.20 (0%)

N/A
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

-0.23 (0%)

N/A
ISRCF iShares V Public Limited .. 0.00 % 0.00 %

+0.10 (+0%)

N/A
ISRHF iShares V Public Limited .. 0.00 % 0.00 %

-0.06 (0%)

N/A
ISRUF iShares V Public Limited .. 0.00 % 0.00 %

+0.05 (+0%)

N/A
ISRZF iShares II Public Limited.. 0.00 % 0.00 %

+0.54 (+0%)

N/A
ISRIF 0.00 % 0.00 %

N/A

N/A
ISRVF iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
ISRWF iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
ISRNF 0.00 % 0.00 %

N/A

N/A
ISRRF 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.86% 29% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.86% 29% F 8% B-
Trailing 12 Months  
Capital Gain 15.56% 79% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.56% 71% C- 82% B
Trailing 5 Years  
Capital Gain 39.57% 85% B 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.57% 69% C- 40% F
Average Annual (5 Year Horizon)  
Capital Gain 13.16% 71% C- 76% C+
Dividend Return 13.16% 71% C- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.82% 43% F 20% F
Risk Adjusted Return 30.73% 71% C- 48% F
Market Capitalization 38.25B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector